Sector
Healthcare
Industry
Biotechnology
Employees
80
First IPO Date
November 05, 2021
| Name | Title | Pay | Year Born |
| Mai-Britt Zocca | Founder, President, Chief Executive Officer, Principal Financial Officer & Director | 908,461 | 1968 |
| Devin Whittemore Smith | Secretary, General Counsel & Chief Compliance Officer | 621,800 | 1968 |
| Amy Sullivan | Principal Accounting Officer & CFO | 650,708 | 1970 |
| Qasim Iftikhar Ahmad | Chief Medical Officer | 709,800 | 1972 |
| Eric Faulkner | Chief Technical Officer | 0 | N/A |
| Inge Marie Svane | Founder & Clinical Advisor | 0 | N/A |
| Mads Hald Andersen | Co-Founder & Scientific Advisor | 0 | N/A |
| Anders Ljungqvist | Founder | 0 | N/A |
| Faical Miyara | Chief Business Officer | 0 | N/A |
| Daniel G. Mannix | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Per Thor Straten | Founder | 0 | N/A |
| Marjan Shamsaei | Senior Vice President of Commercial Development & Portfolio Lead | 0 | N/A |
IO Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating immune-modulating cancer treatments. These therapies leverage its proprietary T-win technology platform. The company's primary investigational drug, IO102-IO103, is engineered to counteract immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and programmed death-ligand (PD-L1). This candidate is progressing through Phase 2 clinical trials for melanoma and is also being evaluated in Phase 1 trials across a range of other cancers, including lung, head and neck, bladder, and melanoma. Additionally, IO Biotech is developing IO112, a distinct product candidate. IO112 comprises a single Arginase 1-derived peptide designed to specifically target T cells that identify epitopes originating from Arginase 1, aiming to treat various malignancies. Established in 2014, the company is headquartered in Copenhagen, Denmark.